2021
Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy
Foldi J, Rozenblit M, Park TS, Knowlton CA, Golshan M, Moran M, Pusztai L. Optimal Management for Residual Disease Following Neoadjuvant Systemic Therapy. Current Treatment Options In Oncology 2021, 22: 79. PMID: 34213636, DOI: 10.1007/s11864-021-00879-4.Peer-Reviewed Original ResearchConceptsPathologic complete responseResidual cancerClinical trialsAdjuvant therapyExcellent long-term disease-free survivalLong-term disease-free survivalAxillary lymph node dissectionHuman epidermal growth factor receptor 2Early-stage breast cancerEpidermal growth factor receptor 2Post-mastectomy breastSystemic adjuvant therapyInternal mammary nodesLymph node dissectionNeoadjuvant systemic therapyDisease-free survivalGrowth factor receptor 2Minimal residual disease monitoringRecurrence-free survivalType of surgeryPivotal clinical trialsOngoing clinical trialsFactor receptor 2Residual disease monitoringAccurate prognostic estimates
2019
Standard Tangential Radiation Fields Do Not Provide Incidental Coverage to the Internal Mammary Nodes
Loganadane G, Kassick M, Kann BH, Young MR, Knowlton CA, Evans SB, Higgins SA, Belkacemi Y, Potenziani M, Saltmarsh N, Wilson LD, Moran MS. Standard Tangential Radiation Fields Do Not Provide Incidental Coverage to the Internal Mammary Nodes. Practical Radiation Oncology 2019, 10: 21-28. PMID: 31394256, DOI: 10.1016/j.prro.2019.07.014.Peer-Reviewed Original ResearchConceptsInternal mammary nodesClinical target volumePlanning target volumeIMN chainMean doseTangential radiation fieldsTarget volumePostmastectomy radiationMammary nodesRadiation therapyAdjuvant whole breast radiation therapyWhole breast radiation therapyRegional nodal radiationConformal radiation therapyNodal radiationPrimary endpointMedian doseTherapeutic coverageStudy cohortTherapeutic dosesBreast cancerIncidental doseAxillary fieldKruskal-Wallis testSupraclavicular field